News - Starpharma

Latest News

$DEP® irinotecan synergistic with Lynparza® in refractory human colon cancer model$

DEP® irinotecan synergistic with Lynparza® in refractory human colon cancer model

Sep 12th, 2019

Starpharma today announced that its patented clinical stage nanoparticle formulation, DEP^® irinotecan, showed significantly enhanced efficacy benefits over standard irinotecan (Camptosar^®) and olaparib (Lynparza^®) alone and in combination, in an irinotecan-refractory HT-29 human colon cancer xenograft model.

VivaGel® BV regulatory approvals continue in Asia

Sep 3rd, 2019

Starpharma today announced that it has received a further regulatory approval in an Asian country for VivaGel^® BV. This approval follows multiple country approvals in the region as previously announced on 15 August 2019. Mundipharma will be rolling-out the product in Asia under the brand name BETADINE^TM BV Gel.

Positive results with Targeted DEP® using antibody fragment in human ovarian cancer model

Aug 29th, 2019

Starpharma today announced that treatment with a novel HER-2 Targeted DEP^® conjugate from its internal Targeted DEP^® program resulted in tumour regression and 100% survival in a preclinical human ovarian cancer model.

Annual report and full year financial results

Aug 28th, 2019

Starpharma today released its annual report and financial results for the year ended 30 June 2019.

In the media

Markets Live: Starpharma shares rise 13 per cent following Australian launch of VivaGel BV

Apr 16th, 2019

The Australian Financial Review reported Starpharma’s share price rose 13 per cent following the company’s announcement that VivaGel® BV was launched nationwide in Australia. The article noted this was the first of many launches for the breakthrough BV product.

Read the full coverage here (paywall)

Starpharma’s US license for VivaGel® BV covered by Biotech Dispatch

Dec 20th, 2018

Biotech Dispatch featured the news that Starpharma had signed a sales and marketing license agreement for VivaGel® BV for the US market with ITF Pharma. The piece highlighted that upon launch, VivalGel® BV will be ITF Pharma’s top priority women’s health product.

To read the article, click here.

Starpharma’s $142M+ US license deal for VivaGel® BV featured in Proactive Investors

Dec 20th, 2018

Online investor portal Proactive Investors highlighted Starpharma’s VivaGel® BV US license deal with ITF Pharma, worth $142 million plus escalating double digit royalties. The piece noted ITF Pharma’s strong pedigree in women’s health and their high-calibre team.

To read the article, click here.

Small Caps publication covers DEP® irinotecan candidate’s positive performance in pancreatic cancer model

Sep 5th, 2018

Small Caps, a specialist investment publication, covered the positive news that Starpharma’s DEP® irinotecan showed complete tumour regression and 100% survival in a human pancreatic cancer model.

Read the full article here.